EDUARDO
DÍAZ-RUBIO GARCÍA
Investigador hasta 2020
Hospital Virgen del Camino
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Virgen del Camino (8)
2022
-
Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer
Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210
2019
-
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
Critical Reviews in Oncology/Hematology, Vol. 134, pp. 39-45
2018
-
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
European Journal of Cancer, Vol. 101, pp. 263-272
-
Matrix Metalloproteinase 1 as a Novel Biomarker for Monitoring Hepatocellular Carcinoma in Liver Transplant Patients
Transplantation Proceedings, Vol. 50, Núm. 2, pp. 623-627
2015
-
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer
Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541
2014
-
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data
The Lancet Oncology, Vol. 15, Núm. 4, pp. 406-414
1991
-
The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide): A randomized, double-blind, Cross-over trial
Acta Oncologica, Vol. 30, Núm. 3, pp. 339-342